药物筛选发现来氟米特可用于治疗TTC7A缺陷所致炎症性肠病
TTC7A基因突变导致严重且难治的肠道上皮与免疫缺陷,表现为凋亡性小肠结肠炎、多发性肠闭锁和复发性肠狭窄。研究者通过高通量药物筛选发现来氟米特可降低TTC7A敲除细胞中caspase 3和7活性达96%,并在斑马鱼模型和患者来源结肠类器官中验证其恢复肠道动力、减轻肠管狭窄和改善细胞存活的作用,提示来氟米特可能被重新用于治疗TTC7A缺陷。
要点
- 来氟米特在TTC7A敲除细胞中降低caspase 3和7活性达96%。
- 来氟米特可提高TTC7A缺陷细胞中磷酸化AKT和XIAP水平,减少cleaved caspase 3。
- 在ttc7a-/-斑马鱼中,来氟米特改善肠道动力、减轻肠管狭窄并增加肠细胞存活。
核心结论
- 来氟米特在TTC7A敲除细胞中减少凋亡并激活AKT信号,在斑马鱼模型中恢复肠道动力、减轻肠管狭窄并增加肠细胞存活,可能被重新用于治疗TTC7A缺陷。
研究设计与样本
- 研究采用高通量药物筛选,在TTC7A敲除的HAP1细胞中筛选可降低caspase 3和7活性、减少凋亡易感性的美国FDA批准药物。
- 在稳定表达患者来源TTC7A点突变的HeLa细胞中验证候选药物效果,并通过免疫印迹分析细胞信号通路。
- 在ttc7a基因破坏的斑马鱼模型及患者活检来源的结肠类器官中测试候选药物效果,并进行肠道蠕动实时成像和组织学分析。
主要发现
- TTC7A敲除HAP1细胞形态异常并发生凋亡,与活性caspase 3和7水平升高有关。
- 来氟米特使TTC7A敲除细胞中caspase 3和7活性降低96%。
- TTC7A敲除细胞中cleaved caspase 3升高、磷酸化AKT和XIAP水平降低,来氟米特处理后磷酸化AKT和XIAP升高、cleaved caspase 3降低。
- 在ttc7a-/-斑马鱼中给予来氟米特可增加肠道动力、减轻肠道狭窄、增加肠细胞存活、增大肠腔空间并恢复绒毛和杯状细胞形态。
- 患者来源结肠类器官暴露于来氟米特后细胞存活、极性和转运功能均增加。
临床怎么用
- 对于TTC7A缺陷所致严重肠道病变且常规治疗无效的患者,来氟米特可能作为候选药物进行重新定位研究。
局限性
- 研究主要在细胞、斑马鱼和类器官模型中进行,尚缺乏人体临床试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mutations in the tetratricopeptide repeat domain 7A gene (TTC7A) cause intestinal epithelial and immune defects. Patients can become immune deficient and develop apoptotic enterocolitis, multiple intestinal atresia, and recurrent intestinal stenosis. The intestinal disease in patients with TTC7A deficiency is severe and untreatable, and it recurs despite resection or allogeneic hematopoietic stem cell transplant. We screened drugs for those that prevent apoptosis of in cells with TTC7A deficiency and tested their effects in an animal model of the disease. METHODS: We developed a high-throughput screen to identify compounds approved by the US Food and Drug Administration that reduce activity of caspases 3 and 7 in TTC7A-knockout (TTC7A-KO) HAP1 (human haploid) cells and reduce the susceptibility to apoptosis. We validated the effects of identified agents in HeLa cells that stably express TTC7A with point mutations found in patients. Signaling pathways in cells were analyzed by immunoblots. We tested the effects of identified agents in zebrafish with disruption of ttc7a, which develop intestinal defects, and colonoids derived from biopsy samples of patients with and without mutations in TTC7A. We performed real-time imaging of intestinal peristalsis in zebrafish and histologic analyses of intestinal tissues from patients and zebrafish. Colonoids were analyzed by immunofluorescence and for ion transport. RESULTS: TTC7A-KO HAP1 cells have abnormal morphology and undergo apoptosis, due to increased levels of active caspases 3 and 7. We identified drugs that increased cell viability; leflunomide (used to treat patients with inflammatory conditions) reduced caspase 3 and 7 activity in cells by 96%. TTC7A-KO cells contained cleaved caspase 3 and had reduced levels of phosphorylated AKT and X-linked inhibitor of apoptosis (XIAP); incubation of these cells with leflunomide increased levels of phosphorylated AKT and XIAP and reduced levels of cleaved caspase 3. Administration of leflunomide to ttc7a-/- zebrafish increased gut motility, reduced intestinal tract narrowing, increased intestinal cell survival, increased sizes of intestinal luminal spaces, and restored villi and goblet cell morphology. Exposure of patient-derived colonoids to leflunomide increased cell survival, polarity, and transport function. CONCLUSIONS: In a drug screen, we identified leflunomide as an agent that reduces apoptosis and activates AKT signaling in TTC7A-KO cells. In zebrafish with disruption of ttc7a, leflunomide restores gut motility, reduces intestinal tract narrowing, and increases intestinal cell survival. This drug might be repurposed for treatment of TTC7A deficiency.
引用
- Jardine S, Anderson S, Babcock S, et al. Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Disease Caused by TTC7A Deficiency. Gastroenterology. 2019. PMID: 31743734. doi:10.1053/j.gastro.2019.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。